The Importance of Apolipoprotein E Genetic Testing in the Era of Amyloid Lowering Therapies.
作者信息
Ronay Stephen, Tsao Jack W
机构信息
NYU Langone, NY.
出版信息
Neurol Clin Pract. 2024 Apr;14(2):e200258. doi: 10.1212/CPJ.0000000000200258. Epub 2024 Jan 5.
Abstract
摘要
相似文献
1
The Importance of Apolipoprotein E Genetic Testing in the Era of Amyloid Lowering Therapies.
Neurol Clin Pract. 2024 Apr;14(2):e200258. doi: 10.1212/CPJ.0000000000200258. Epub 2024 Jan 5.
2
Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.
Neurol Clin Pract. 2024 Apr;14(2):e200230. doi: 10.1212/CPJ.0000000000200230. Epub 2024 Jan 5.
3
Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases.
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):200-210. doi: 10.1016/j.bbadis.2016.10.010. Epub 2016 Oct 18.
4
[Significance and Response to APOE Genetic Testing in the Anti-amyloid-β Therapy Era].
Brain Nerve. 2024 Sep;76(9):1029-1034. doi: 10.11477/mf.1416202728.
5
Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer's Disease.
Int J Mol Sci. 2024 Nov 8;25(22):12029. doi: 10.3390/ijms252212029.
6
Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
J Integr Neurosci. 2021 Jun 30;20(2):277-286. doi: 10.31083/j.jin2002027.
7
Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.
Eur J Prev Cardiol. 2020 Aug;27(12):1255-1268. doi: 10.1177/2047487319871733. Epub 2019 Sep 2.
8
Potential role of apolipoprotein-E in fibrillogenesis.
Am J Pathol. 1994 Sep;145(3):526-30.
9
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.
Brain. 2012 Jul;135(Pt 7):2155-68. doi: 10.1093/brain/aws127. Epub 2012 May 26.
10
Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.
Brain. 2016 Jan;139(Pt 1):174-92. doi: 10.1093/brain/awv318. Epub 2015 Nov 2.
引用本文的文献
1
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia.
Alzheimers Res Ther. 2024 Oct 11;16(1):219. doi: 10.1186/s13195-024-01595-5.
2
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?
J Prev Alzheimers Dis. 2024;11(4):897-902. doi: 10.14283/jpad.2024.83.
本文引用的文献
1
Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.
Neurol Clin Pract. 2024 Apr;14(2):e200230. doi: 10.1212/CPJ.0000000000200230. Epub 2024 Jan 5.
2
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
3
Lecanemab in Early Alzheimer's Disease.
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
Alzheimers Res Ther. 2022 Apr 26;14(1):60. doi: 10.1186/s13195-022-01003-w.
5
A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.
Neuron. 2019 Mar 6;101(5):820-838. doi: 10.1016/j.neuron.2019.01.056.
6
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
Science. 1993 Aug 13;261(5123):921-3. doi: 10.1126/science.8346443.
Zotero 插件